Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application. (10th October 2022)

• Record Type: Journal Article
• Authors: Xu, Ruihan; Du, Shiyao; Zhu, Junmeng; Meng, Fanyan; Liu, Baorui
• Is Part Of: Cancer letters. Volume 546(2022)
• Publication Date: 2022-10-10
• Subjects: Adoptive cell therapy -- Personalized immunotherapy -- Public neoantigen -- Solid tumors -- TCR; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2022.215840
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: T cell receptor-engineered T (TCR-T) cells targeting neoantigens present potential immunotherapy for solid tumors. With the continuous optimization of the entire production procedures, the manufacturing process of TCR-T cells is becoming more efficient and productive. However, clinical-scale manufacturing of TCR-T cells still encounters tremendous challenges. Here, we summarize the latest progress of neoantigen-targeted TCR-T cell therapy and focus on the technical difficulties in preparing personalized neoantigen-targeted TCR-T cells and the challenges in clinical applications. Possible approaches for improving TCR-T cell therapy are discussed as well in this review. Highlights: Neoantigen-targeted TCR-T cell therapy is one of the most promising immunotherapies for solid tumors. Neoantigen-targeted TCR-T cell therapy has good safety and efficacy. The timely and effective identification of neoantigens is still the main obstacle to personalized tumor immunotherapy. The establishment of a shared neoantigen TCR library shortens the time of neoantigen identification.